Evidence map›Paper›PMID 40785977›Full record

ArticleChemMedChem2025

Development of Dual Aurora-A and Aurora-B Degrading PROTACs for

Sydney E Nelson, James R Tucker, Madelen G Prado, Lillian C Tierney, Sarah L Quigley, Andrew T Lumpkin, Cayden J Dodd, Viola Hasko, Savannah L Howie, Aastha and 4 more

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Discovery of the first-in-class Aurora B kinase selective degrader.European journal of medicinal chemistry · 2025
    Article
  6. Review
  7. Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sydney E NelsonDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
James R TuckerDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Madelen G PradoDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Lillian C TierneyDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Sarah L QuigleyDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Andrew T LumpkinDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Cayden J DoddDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Viola HaskoDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
Savannah L HowieDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).
AasthaDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63130 (USA).
Britton K OdyDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303 (USA).
Jun YinDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA 30303 (USA).
Jennifer M HeemstraDepartment of Chemistry, Washington University in St. Louis, St. Louis, MO 63130 (USA).
Mark TurlingtonDepartment of Chemistry and Biochemistry, Berry College, Mount Berry, GA 30149 (USA).

Funding

Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity.R01GM104498 · NIGMS · UNIVERSITY OF CHICAGO · PI KIYOKAWA, HIROAKI, YIN, JUN · 2013 to 2021
$3.2M
A chemical biology toolbox for RNA post-transcriptional modification and captureR35GM144075 · NIGMS · WASHINGTON UNIVERSITY · PI Jennifer Heemstra · 2022 to 2026
$2.0M
NIGMS NIH HHS R01 GM104498NIGMS NIH HHS R35 GM144075
6 · The paper itself

Abstract

In neuroblastoma,

Indexed as

Antineoplastic AgentsAurora Kinase AAurora Kinase BNeuroblastomaProtein Kinase InhibitorsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureN-Myc Proto-Oncogene ProteinProteolysisProteolysis Targeting ChimeraStructure-Activity RelationshipAntineoplastic AgentsAURKA protein, humanAURKB protein, humanAurora Kinase AAurora Kinase BMYCN protein, humanN-Myc Proto-Oncogene ProteinProtein Kinase InhibitorsProteolysis Targeting ChimeraAurora-AAurora-BneuroblastomaN-MycPROTAC

Identifiers

PMID40785977
PMCPMC12331210

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.